DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Eftilagimod alpha
Eftilagimod alpha
Of Eftilagimod Alpha
Eftilagimod Alpha) in Metastatic Breast Cancer and Other Settings
The Evolving Landscape of `Next-Generation' Immune
IMP321) with Either Chemotherapy Or Anti-PD-1 Therapy
Corporate Presentation May 2021
Eftilagimod Alpha (IMP321)
Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies
Immutep Limited
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
Understanding LAG-3 Signaling
Immutep Corporate Presentation 2020
Next Generation of Immune Checkpoint Inhibitors and Beyond Julian A
Results of a Phase I Trial with Metastatic Melanoma
2020 Medicines in Development ꟷ Cancer
IMP321 Webcast
Novel Immune Checkpoint Targets: Moving Beyond PD-1 and CTLA-4 Shuang Qin1, Linping Xu2, Ming Yi1, Shengnan Yu1, Kongming Wu1,2* and Suxia Luo2*
Harnessing NK Cell Checkpoint-Modulating Immunotherapies
Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC and HNSCC
Top View
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
Immutep Limited
Potential Strategies to Improve the Effectiveness of Drug Therapy by Changing Factors Related to Tumor Microenvironment
Immutep Investor Presentation
Eftilagimod Alpha, a Soluble Lymphocyte Activation Gene-3 (LAG-3) Protein Plus Pembrolizumab in Patients with Metastatic Melanoma
Primary Efficacy Results from AIPAC
Eftilagimod Alpha (IMP321)
Immune Checkpoints and CAR-T Cells: the Pioneers in Future Cancer Therapies?
(FDA) Approved Abecma
LAG-3 Immune Checkpoint Price Target AUD0.078 Price AUD0.036
Eftilagimod Alpha, a Soluble Lymphocyte Activation Gene-3 (LAG-3) Protein Plus Pembrolizumab in Patients with Metastatic Melanoma
Leading the LAG-3 Immunotherapy Charge Into Immuno-Oncology and Autoimmune Disease; Initiating at Buy, $7.75 PT Dylan Dupuis, Ph.D